# Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

> **NCT05760378** · PHASE3 · RECRUITING · sponsor: **Fudan University** · enrollment: 223 (estimated)

## Conditions studied

- Triple-Negative Breast Cancer

## Interventions

- **DRUG:** Famitinib
- **DRUG:** Camrelizumab
- **DRUG:** nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin

## Key facts

- **NCT ID:** NCT05760378
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-17
- **Primary completion:** 2025-01-01
- **Final completion:** 2027-01-01
- **Target enrollment:** 223 (ESTIMATED)
- **Last updated:** 2024-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05760378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05760378, "Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05760378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*